ONLINE FIRST

No Cerebral or Cervical Venous Insufficiency in US Veterans With Multiple Sclerosis

Ellen Marder, MD; Pramod Gupta, MD; Benjamin M. Greenberg, MD; Elliot M. Frohman, MD, PhD; Amer M. Awad, MD; Bridget Bagert, MD; Olaf Stuve, MD, PhD

Objective: To determine if chronic cerebral venous insufficiency exists in patients with multiple sclerosis (MS) using ultrasonography and 4-dimensional color Doppler ultrasonography examination and unverified criteria proposed by Zamboni et al.

Design: Patients with MS and clinically isolated syndrome were matched by age and sex with subjects with migraine or no neurological disease. All subjects underwent gray-scale, color, and spectral Doppler ultrasonography examination of the internal jugular veins (IJVs), vertebral veins, and deep cerebral veins for stenosis, absence of signal, and reflux.

Setting: Academic MS center.

Patients: All patients with MS fulfilled revised McDonald criteria for the diagnosis of MS. Patients with clinically isolated syndrome exhibited a typical transient focal neurological deficit and had magnetic resonance imaging lesions typical of MS. Control subjects were recruited from the VA migraine clinic or staff.

Main Outcome Measures: Five parameters of venous outflow used by Zamboni et al were examined: (1) IJV or vertebral vein reflux, (2) deep cerebral vein reflux, (3) IJV stenosis, (4) absence of flow in IJVs or vertebral veins, and (5) change in cross-sectional area of the IJV with postural change.

Results: There was no significant difference in the number and type of venous outflow abnormalities in patients with MS compared with controls.

Conclusion: This study does not support the theory that chronic cerebral venous insufficiency exists in MS.


MULTIPLE SCLEROSIS (MS) is an inflammatory demyelinating and degenerative disease of the central nervous system (CNS). The cause of MS is unknown. Although MS may affect any part of the CNS, perivenous inflammation and demyelination have long been recognized as the histopathological signature of the disorder. Evidence suggests that this microscopically conspicuous profile signifies disruption of the blood-brain barrier associated with an immune response that is either the initial cause of the MS lesion or secondary to another immunogenic event within the CNS.

According to a hypothesis proposed by Zamboni and colleagues, elevated cerebral venous pressure due to vascular abnormalities such as venous stenosis or valve incompetence cause impaired venous drainage and as a result cerebral venous hypertension. The increased pressure mechanically disrupts the blood-brain barrier allowing blood to enter the brain and initiate, or participate in, an inflammatory response.

CME available online at www.jamaarchivescme.com and questions on page 1503

For editorial comment see page 1510

Several recently published studies suggest that the perivenous inflammation and perhaps the disease itself are initiated by cerebral venous hypertension or chronic cerebrospinal venous insufficiency (CCSVI). These investigators reported that impairment of cerebrospinal venous drainage due to venous stenosis or valvular incompetence was present by ultrasonography in 100% of patients with MS studied but not in any subjects without MS. In another study, Zamboni et al report disease phenotype-specific venous
outflow characteristics in patients with MS. Finally, the same investigators suggest that surgically correcting the stenosis identified by ultrasonography has a beneficial effect on the MS disease course.10

Other investigators have not been able to reproduce the findings published by Zamboni et al7 in a small number of both patients with MS and control subjects by extracranial and transcranial color-coded ultrasonography without significant differences between the 2 groups.11

The purpose of this study was to reproduce recent ultrasonography observations made by Zamboni and coworkers in US veterans of the armed forces with MS.

METHODS

SUBJECTS AND CLINICAL ASSESSMENTS

This study was approved by the Dallas, Texas, VA Medical Center Internal Review Board, and informed consent was obtained from all subjects.

ULTRASONOGRAPHY STUDIES

All examinations were performed with a phased-array ultrasonography system (Logic 9; GE Healthcare, Milwaukee, Wisconsin) equipped with 8-MHz linear and 2-MHz sector transducer probes. For extracranial evaluation, an 8-MHz transducer was used and for transcranial evaluation, a 2-MHz probe. B-mode, gray-scale, color Doppler, and spectral Doppler ultrasonography were used while interrogating each vein. Each subject was investigated first in the supine and then in an upright (90°, sitting) position, after end inspiration and end expiration. Studies were performed by an ultrasonographer blinded to subject diagnosis and interpreted by a radiologist blinded to subject diagnosis.

Specifically, 5 criteria defined by Zamboni et al necessary for the diagnosis of CCSVI, and which purportedly increase cerebral venous pressure, were investigated: (1) reflux more than 88 seconds in the internal jugular veins (IJVs) and/or vertebral veins (VVs), (2) reflux in the deep cerebral veins (DCVs), (3) B-mode evidence of proximal IJV stenosis, defined as local cross-sectional area (CSA) reduction of 50% or more in the supine position (0°), (4) flow not Doppler detectable in both IJVs and/or both VVs, and (5) missing IJV diameter decrease during inspiration and expiration. Studies were performed by insonating their entire accessible length following the suggestion of Zamboni et al. Cross-sectional area, stenosis was defined as a local CSA reduction of 50% or more, and venous reflux, signifying a flow reversal from its physiological direction for a duration of more than 0.88 second, was studied.

Transcranial assessment of the intracranial venous vasculature was performed following established criteria for transcranial color-coded duplex ultrasonography. Both transtemporal and transoccipital approaches were used in this study. With the transtemporal approach, DCVs were identified on each side and analyzed in both 0° and 90° positions during inspiration and expiration. Similarly, with the transoccipital approach, the transverse sinus (TS) was analyzed on each side.

Blood volume flow and blood flow velocity were recorded in these veins in each position during end inspiration and end expiration. Physiological intracranial venous flow is monodirectional. As per criteria used by Zamboni et al, bidirectional flow was assessed when, in at least 1 of these postural conditions, flow reversal was less than 0.5 second and for venous reflux, flow reversal was more than 0.5 second.

STATISTICAL METHODS

The sample size was based on 2 power analyses. One analysis was performed using the percentage of differences between groups in the Zamboni et al study7 and the other, using their odds ratio of 43. Based on these calculations, it was determined that 6 patients with MS and 6 controls were required to achieve a power of 0.90 with an α=.05. These requirements were met and exceeded in this study. Pearson χ2 tests were used to test our null hypothesis, namely that the frequency distribution of venous ultrasonography characteristics as defined by Zamboni et al9 in our population was consistent with those observed by Zamboni et al. Correlations between continuous and categorical variables were assessed using the Mann-Whitney U test. P values <.05 were considered significant.

RESULTS

PATIENTS

Eighteen patients (3 women and 15 men) with a diagnosis of definite MS fulfilling revised McDonald criteria12 or clinically isolated syndrome (CIS) were recruited from the VA MS clinic and included in the study. The mean (SD) age of the patients was 55.2 (11.6) years. Six patients had relapsing-remitting MS, 1 had CIS, 10 patients had secondary progressive MS, and 1 patient had primary progressive MS. Patients who had had a relapse or received steroids in the last 30 days were excluded from the study.

Eleven age- and sex-matched subjects (4 women and 7 men) with migraine headaches or individuals without a neurological diagnosis were recruited as a reference population. The mean (SD) age of the reference group was 55.3 (11.1) years. Subjects with a history of cerebral venous thrombosis, transient global amnesia, thrombosis of the jugular vein(s), central venous catheter in the IJV, head and neck surgery, or heart or lung disease were not eligible for this study.

There was also no significant difference between the patients with MS and the control subjects with respect to age (z=0.24; P=.82) or sex (χ2=1.2; P=.26). The results for specific criteria as defined by Zamboni et al are shown later. Demographics of patients with MS and controls are summarized in Table 1.
Zamboni Criteria 1 to 5 in Patients With MS and Control Subjects

Of the 18 patients with MS, 4 patients met 1 definition for CCSVI proposed by Zamboni and coworkers.7 In 2 patients, there was a negative change in the left IJV CSA. There was reflux in the right TS in 1 patient. Among the 11 control subjects, 4 met 1 definition for CCSVI proposed by Zamboni and coworkers. Two individuals displayed a negative change in CSA in the left IJV. No right VV flow was seen in 1 control and no flow in the left VV was seen in 1 control. There was no significant difference in the number of ultrasonography abnormalities between patients with MS and controls (Table 2).

TECHNICAL ASPECTS OF CEREBRAL AND CERVICAL VENOUS ULTRASONOGRAPHY

The total examination time was approximately 60 minutes in each subject. Insonation of the TSs was not performed in 1 patient with MS; the right TS was not seen in 1 patient with MS. In 1 control subject, the DCV and TS were not seen on either side; in 1 control subject, the TS was not seen on either side; in 1 control subject, the left TS was not seen; and in 1 control subject, the left VV was not seen.

ZAMBONI CRITERIA 1 TO 5 IN PATIENTS WITH MS AND CONTROL SUBJECTS

Table 1. Demographics of Patients With MS and Controls

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Sample Size</th>
<th>Age, y Mean (SD)</th>
<th>Sex (F/M)</th>
<th>Disease Duration, y, Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with MS</td>
<td>18</td>
<td>55.2 (1.6)</td>
<td>3/15 (82.4% M)</td>
<td>20.8 (2-40)</td>
</tr>
<tr>
<td>RRMS</td>
<td>6</td>
<td></td>
<td></td>
<td>12.5 (2-29)</td>
</tr>
<tr>
<td>SPMS</td>
<td>10</td>
<td></td>
<td></td>
<td>23.9 (11-40)</td>
</tr>
<tr>
<td>CIS</td>
<td>1</td>
<td></td>
<td></td>
<td>10b</td>
</tr>
<tr>
<td>PPMS</td>
<td>1</td>
<td></td>
<td></td>
<td>20b</td>
</tr>
<tr>
<td>Controls</td>
<td>11</td>
<td>55.3 (11.1)</td>
<td>4/7 (63.6% M)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: CIS, clinically isolated syndrome; MS, multiple sclerosis; NA, not applicable; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.

a The Mann-Whitney U test showed no significant difference between patients with MS and controls in age (z=0.24; P=.82). The χ² test showed no significant difference between the groups in sex (χ²=1.2; P=.26).

b One patient only.

Table 2. CCSVI Criteria

<table>
<thead>
<tr>
<th>CCSVI Criteria</th>
<th>Reflux IJV/VV</th>
<th>Reflux DCV</th>
<th>IJV Stenosis</th>
<th>Absent Flow IJV/VV</th>
<th>Negative Change in CSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>RRMS</td>
<td>0/6</td>
<td>0/6</td>
<td>0/6</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td>SPMS</td>
<td>0/10</td>
<td>1/10</td>
<td>0/10</td>
<td>1/10</td>
<td>2/10</td>
</tr>
<tr>
<td>CIS</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td>PPMS</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td>Controls</td>
<td>0/11</td>
<td>0/11</td>
<td>0/11</td>
<td>2/11</td>
<td>2/11</td>
</tr>
</tbody>
</table>

Abbreviations: CCSVI, chronic cerebrospinal venous insufficiency; CIS, clinically isolated syndrome; CSA, cross-sectional area; DCV, deep cerebral vein; IJV, internal jugular vein; MS, multiple sclerosis; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS; VV, vertebral vein.

The χ² test showed no significant difference between patients with MS and controls (χ²=1.2; P=.26).

COMMENT

This study failed to detect a significant difference in the Zamboni et al criteria for impairment to cerebral venous drainage in patients with MS compared with control subjects. A number of investigators have attempted to reproduce the Zamboni et al results using their criteria and methods.11,13-16
The earliest clinical event in patients with MS is termed a clinically isolated syndrome. If CCSVI plays a pathogenic role in MS, one would expect to see evidence of it at disease onset. Baracchini et al\(^1\) performed transcranial-extracranial Doppler with high-resolution color-coded duplex ultrasonography on 50 patients with CIS at high risk for conversion to MS, as well as 50 age- and sex-matched controls. A total of 8 of 50 patients (16%) with CIS fulfilled CCSVI criteria. In addition, 7 of 8 patients with CIS underwent selective venography of the IJVs and azygos veins. In 6 of 7 of these patients, there was normal or regular IJV and azygos drainage. The remaining patient had right IJV hypoplasia. Ultrasonography criteria for CCSVI abnormalities were not confirmed on venography, suggesting ultrasonography may not be an accurate method for identification of venous abnormalities.

Zivadinov and colleagues\(^1\) studied 499 subjects, 289 with MS, 163 healthy controls, 260 with other neurological diseases, and 21 patients with CIS. The CCSVI criteria were met by subjects in all groups (56.1% with MS, 42.3% with other neurological diseases, 38% with CIS, and 22.7% healthy controls). Despite the significantly higher incidence of CCSVI in patients with MS that was detected in this study, it is substantially lower than the 100% incidence found by Zamboni et al. Based on these findings, the presence of CCSVI is neither sensitive nor specific for MS. Furthermore, 20% of subjects had no DCV assessment because of failure to identify these structures or the presence of artifact, suggesting the presence of venous abnormalities due to either technical factors or subjectivity.

Current treatments for MS are only partially effective, some aimed at suppressing inflammation by broadly modulating or suppressing the immune system and others, by preventing inflammatory cells from entering the CNS through a disrupted blood-brain barrier. The most effective treatments have a potential risk of serious morbidity and even mortality. We welcome new insights into the disease process and especially the promise of a single effective treatment. However, our findings and those of other investigators call into question whether CCSVI plays a pathogenic role in a substantial fraction of patients with MS and whether it presents a valid therapeutic target. The results presented herein refute that hypothesis and corroborate those of other investigators who have recently been unable to replicate the Zamboni et al observations.

References:


